Milestone Pharmaceuticals prices $52.5M public offering of common shares and warrants

Milestone Pharmaceuticals Inc.

Priced $52.5M offering of 31.5M common shares + Series A and B warrants at $1.50/unit; 3.5M pre-funded warrants at $1.499/unit.
Net proceeds expected ~$48.7M after underwriting commissions and expenses.
Series A warrants exercisable at $1.50 for 1 year; Series B at $1.875 for 5 years, with mandatory exercise trigger at $3.50 VWAP.
Proceeds to fund etripamil clinical development and commercial launch for paroxysmal supraventricular tachycardia (PSVT).
Offering led by TD Cowen, Piper Sandler, Wells Fargo; expected to close July 14, 2025.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.